Research into chimeric antigen receptor-modified T cell (CAR-T) therapy targeting GD2 is advancing as a potential treatment for patients with diffuse midline gliomas characterized...
The diagnosis of diffuse midline gliomas is evolving with the integration of advanced biopsy techniques, biomarker testing, and coordinated pathology efforts. These tumors, often...